Acepromazine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (6)Carriers (1)Transporters (1)

Targets (6)Carriers (1)Transporters (1)Biointeractions (7)

Identification

Name

Acepromazine

Accession Number

DB01614

Type

Small Molecule

Groups

Approved, Vet Approved

Description

Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-[10-(3-DIMETHYLAMINO-propyl)-10H-phenothiazin-2-yl]-ethanone

10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone

10-(3-dimethylaminopropyl)phenothiazine-3-ethylone

Acetazine

Acetopromazine

Acetylpromazine

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Acepromazine maleate	37862HP2OM	3598-37-6	FQRHOOHLUYHMGG-BTJKTKAUSA-N	Details

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Acezine 2	Not Available
Atravet	Not Available

Brand mixtures

Not Available

Categories

UNII

54EJ303F0R

CAS number

61-00-7

Weight

Average: 326.456
Monoisotopic: 326.145284026

Chemical Formula

C₁₉H₂₂N₂OS

InChI Key

NOSIYYJFMPDDSA-UHFFFAOYSA-N

InChI

InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3

IUPAC Name

1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one

SMILES

CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O

Pharmacology

Indication

Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.

Structured Indications

Not Available

Pharmacodynamics

Acepromazine is one of the phenothiazine derivative psychotropic drugs. Acepromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Acepromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

Mechanism of action

Acepromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
D(2) dopamine receptor	Protein	yes	antagonist	Human	P14416	details
D(1A) dopamine receptor	Protein	yes	antagonist	Human	P21728	details
5-hydroxytryptamine receptor 2A	Protein	yes	antagonist	Human	P28223	details
5-hydroxytryptamine receptor 1A	Protein	yes	antagonist	Human	P08908	details
Alpha-1A adrenergic receptor	Protein	unknown	antagonist	Human	P35348	details
Alpha-1B adrenergic receptor	Protein	unknown	antagonist	Human	P35368	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

3 hours in horses.

Clearance

Not Available

Toxicity

Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	Acepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	Acepromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	Acepromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Acepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
5'-Deoxy-5'-Methylthioadenosine	The serum concentration of Acepromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.	Experimental
7-Nitroindazole	The risk or severity of adverse effects can be increased when Acepromazine is combined with 7-Nitroindazole.	Experimental
Acebutolol	Acepromazine may increase the hypotensive activities of Acebutolol.	Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Aceprometazine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Acepromazine is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Agomelatine.	Approved, Investigational
Alfaxalone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Acepromazine.	Approved, Illicit
Allopregnanolone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Sage 547.	Investigational
Almotriptan	The risk or severity of adverse effects can be increased when Almotriptan is combined with Acepromazine.	Approved, Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Acepromazine.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Acepromazine.	Approved, Illicit, Investigational
Alprenolol	Acepromazine may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Amisulpride	The risk or severity of adverse effects can be increased when Acepromazine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Acepromazine is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Acepromazine.	Approved, Illicit
Amodiaquine	The serum concentration of Acepromazine can be increased when it is combined with Amodiaquine.	Approved
Amoxapine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Amperozide.	Experimental
Amphetamine	Acepromazine may decrease the stimulatory activities of Amphetamine.	Approved, Illicit
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acepromazine.	Approved, Investigational
Arotinolol	Acepromazine may increase the hypotensive activities of Arotinolol.	Approved
Artemether	The serum concentration of Acepromazine can be increased when it is combined with Artemether.	Approved
Artemisinin	The serum concentration of Acepromazine can be increased when it is combined with Artemisinin.	Investigational
Artenimol	The serum concentration of Acepromazine can be increased when it is combined with Dihydroartemisinin.	Approved
Artesunate	The serum concentration of Acepromazine can be increased when it is combined with Artesunate.	Approved
Articaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Asenapine.	Approved
Atenolol	Acepromazine may increase the hypotensive activities of Atenolol.	Approved
Atovaquone	The serum concentration of Acepromazine can be increased when it is combined with Atovaquone.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Azaperone.	Vet Approved
Azelastine	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Acepromazine is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.	Illicit
Befunolol	Acepromazine may increase the hypotensive activities of Befunolol.	Experimental
Benperidol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Acepromazine.	Approved
Benzphetamine	Acepromazine may decrease the stimulatory activities of Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Benzyl alcohol.	Approved
Betaxolol	Acepromazine may increase the hypotensive activities of Betaxolol.	Approved
Betulinic Acid	The serum concentration of Acepromazine can be increased when it is combined with Betulinic Acid.	Investigational
Bevantolol	Acepromazine may increase the hypotensive activities of Bevantolol.	Approved
Bezitramide	Acepromazine may increase the hypotensive activities of Bezitramide.	Experimental, Illicit, Withdrawn
Bismuth Subcitrate	Bismuth Subcitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Bisoprolol	Acepromazine may increase the hypotensive activities of Bisoprolol.	Approved
Bopindolol	Acepromazine may increase the hypotensive activities of Bopindolol.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Acepromazine is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine.	Approved, Illicit
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Brotizolam.	Approved, Withdrawn
Bucindolol	Acepromazine may increase the hypotensive activities of Bucindolol.	Investigational
Bufuralol	Acepromazine may increase the hypotensive activities of Bufuralol.	Experimental, Investigational
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine.	Approved, Investigational
Bupranolol	Acepromazine may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Acepromazine is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Acepromazine is combined with Butamben.	Approved
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Acepromazine.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Acepromazine.	Approved, Illicit, Vet Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Acepromazine.	Approved
Calcium Carbonate	Calcium carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Acepromazine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Acepromazine.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Carisoprodol.	Approved
Carteolol	Acepromazine may increase the hypotensive activities of Carteolol.	Approved
Carvedilol	Acepromazine may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Celiprolol	Acepromazine may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Cetirizine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Acepromazine.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acepromazine.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Acepromazine.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Acepromazine.	Approved
Chloroquine	The serum concentration of Acepromazine can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Chlorphenamine.	Approved
Chlorphentermine	Acepromazine may decrease the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acepromazine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Chlorzoxazone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Acepromazine.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clobazam.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when Acepromazine is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Clonidine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine.	Approved, Illicit
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Acepromazine.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Acepromazine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Acepromazine.	Approved, Illicit
Cyclizine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Acepromazine is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Acepromazine.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Dapoxetine.	Investigational
Dapsone	The serum concentration of Acepromazine can be increased when it is combined with Dapsone.	Approved, Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Acepromazine is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acepromazine.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acepromazine.	Approved, Vet Approved
Dextroamphetamine	Acepromazine may decrease the stimulatory activities of Dextroamphetamine.	Approved, Illicit
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acepromazine.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Acepromazine.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acepromazine.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Acepromazine.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Acepromazine.	Approved, Illicit, Vet Approved
Diethylpropion	Acepromazine may decrease the stimulatory activities of Diethylpropion.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine.	Approved, Illicit
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acepromazine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acepromazine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acepromazine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acepromazine.	Approved, Illicit
Doramectin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Doramectin.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Doxepin.	Approved
Doxycycline	The serum concentration of Acepromazine can be increased when it is combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Acepromazine is combined with DPDPE.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Acepromazine.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Duloxetine is combined with Acepromazine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Acepromazine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Acepromazine is combined with Efavirenz.	Approved, Investigational
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Acepromazine.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Acepromazine.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Entacapone.	Approved, Investigational
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Acepromazine.	Approved
Escitalopram	The risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram.	Approved, Investigational
Esmolol	Acepromazine may increase the hypotensive activities of Esmolol.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Acepromazine.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Acepromazine.	Approved
Ethanol	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Acepromazine.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acepromazine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Acepromazine.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Acepromazine.	Approved, Illicit, Withdrawn
Fenfluramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fenfluramine.	Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fexofenadine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Flibanserin.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Acepromazine.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Acepromazine.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fluvoxamine.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Fospropofol.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Acepromazine.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Acepromazine.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Acepromazine is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Acepromazine.	Approved, Illicit
Gepirone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Acepromazine.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Acepromazine.	Approved, Illicit, Withdrawn
Halofantrine	The serum concentration of Acepromazine can be increased when it is combined with Halofantrine.	Approved
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Acepromazine.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Acepromazine.	Approved
Hydrocodone	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine.	Approved, Illicit
Hydroxyamphetamine	Acepromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.	Approved
Hydroxychloroquine	The serum concentration of Acepromazine can be increased when it is combined with Hydroxychloroquine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine.	Investigational, Withdrawn
Indenolol	Acepromazine may increase the hypotensive activities of Indenolol.	Withdrawn
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acepromazine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Acepromazine.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Ketazolam is combined with Acepromazine.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ketobemidone.	Approved
Labetalol	Acepromazine may increase the hypotensive activities of Labetalol.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Lamotrigine.	Approved, Investigational
Landiolol	Acepromazine may increase the hypotensive activities of Aop200704.	Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Levetiracetam.	Approved, Investigational
Levobunolol	Acepromazine may increase the hypotensive activities of Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Acepromazine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Acepromazine is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acepromazine.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Acepromazine.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine.	Approved, Vet Approved
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Acepromazine.	Approved, Investigational
Lisdexamfetamine	Acepromazine may decrease the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lithium	Lithium may increase the neurotoxic activities of Acepromazine.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Acepromazine is combined with Lofentanil.	Illicit
Loratadine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Acepromazine.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Lorcaserin is combined with Acepromazine.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine.	Approved
Lumefantrine	The serum concentration of Acepromazine can be increased when it is combined with Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Lurasidone.	Approved
Magaldrate	Magaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Withdrawn
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium Hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Vet Approved
Magnesium Trisilicate	Magnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Maprotiline	The risk or severity of adverse effects can be increased when Acepromazine is combined with Maprotiline.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Meclizine.	Approved
Medetomidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Medetomidine.	Vet Approved
Mefloquine	The serum concentration of Acepromazine can be increased when it is combined with Mefloquine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Acepromazine.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Melperone.	Approved
Mephedrone	Acepromazine may decrease the stimulatory activities of Mephedrone.	Investigational
Mephentermine	Acepromazine may decrease the stimulatory activities of Mephentermine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.	Approved, Illicit
Mequitazine	Acepromazine may increase the arrhythmogenic activities of Mequitazine.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Acepromazine.	Approved, Illicit
Methamphetamine	Acepromazine may decrease the stimulatory activities of Methamphetamine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Acepromazine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Acepromazine.	Approved
Methotrimeprazine	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Acepromazine.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Acepromazine is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenidate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Acepromazine.	Approved
Metipranolol	Acepromazine may increase the hypotensive activities of Metipranolol.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.	Approved, Investigational
Metoprolol	Acepromazine may increase the hypotensive activities of Metoprolol.	Approved, Investigational
Metyrosine	Acepromazine may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Acepromazine is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Investigational
Mirtazapine	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mizoribine	The serum concentration of Acepromazine can be increased when it is combined with Mizoribine.	Investigational
MMDA	Acepromazine may decrease the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Investigational
Nadolol	Acepromazine may increase the hypotensive activities of Nadolol.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Acepromazine.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Acepromazine.	Approved, Investigational
Nefazodone	The risk or severity of adverse effects can be increased when Nefazodone is combined with Acepromazine.	Approved, Withdrawn
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Acepromazine.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Acepromazine is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Acepromazine is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Acepromazine.	Approved
Opium	The risk or severity of adverse effects can be increased when Acepromazine is combined with Opium.	Approved, Illicit
Orphenadrine	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant.	Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Acepromazine.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Acepromazine.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Acepromazine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Acepromazine.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Acepromazine.	Approved, Investigational, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Acepromazine.	Approved
Paraldehyde	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.	Approved, Investigational
Penbutolol	Acepromazine may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Acepromazine.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved
Perazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Acepromazine.	Approved
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine.	Approved
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Acepromazine.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenoxyethanol.	Approved
Phentermine	Acepromazine may decrease the stimulatory activities of Phentermine.	Approved, Illicit
Phenytoin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Acepromazine.	Approved
Pindolol	Acepromazine may increase the hypotensive activities of Pindolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Piritramide.	Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pizotifen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pomalidomide.	Approved
Practolol	Acepromazine may increase the hypotensive activities of Practolol.	Approved
Pramipexole	Acepromazine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Acepromazine.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Acepromazine.	Approved
Primaquine	The serum concentration of Acepromazine can be increased when it is combined with Primaquine.	Approved
Primidone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Acepromazine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Acepromazine.	Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.	Approved, Vet Approved
Proguanil	The serum concentration of Acepromazine can be increased when it is combined with Proguanil.	Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Acepromazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Acepromazine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Propoxycaine.	Approved
Propranolol	Acepromazine may increase the hypotensive activities of Propranolol.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Acepromazine is combined with Protriptyline.	Approved
PSD502	The risk or severity of adverse effects can be increased when Acepromazine is combined with PSD502.	Investigational
Pseudoephedrine	Acepromazine may decrease the stimulatory activities of Pseudoephedrine.	Approved
Pyrimethamine	The serum concentration of Acepromazine can be increased when it is combined with Pyrimethamine.	Approved, Vet Approved
Pyronaridine	The serum concentration of Acepromazine can be increased when it is combined with Pyronaridine.	Investigational
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Acepromazine.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Acepromazine.	Approved
Quinacrine	The serum concentration of Acepromazine can be increased when it is combined with Quinacrine.	Approved
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Acepromazine.	Approved
Quinidine	The serum concentration of Acepromazine can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Acepromazine can be increased when it is combined with Quinine.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Acepromazine is combined with Raclopride.	Investigational
Radicicol	The serum concentration of Acepromazine can be increased when it is combined with Radicicol.	Experimental
Ramelteon	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ramelteon.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Acepromazine.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Acepromazine.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ritanserin.	Investigational
Ritobegron	Acepromazine may decrease the stimulatory activities of Ritobegron.	Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Acepromazine.	Approved
Romifidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Romifidine.	Vet Approved
Ropinirole	Acepromazine may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine.	Approved
Rotigotine	Acepromazine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Acepromazine.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Acepromazine.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Acepromazine is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Acepromazine is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine.	Approved, Vet Approved
Sinefungin	The serum concentration of Acepromazine can be increased when it is combined with Sinefungin.	Experimental
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved
Sotalol	Acepromazine may increase the hypotensive activities of Sotalol.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.	Approved, Investigational
Sulfadoxine	The serum concentration of Acepromazine can be increased when it is combined with Sulfadoxine.	Approved
Sulfametopyrazine	The serum concentration of Acepromazine can be increased when it is combined with Sulfametopyrazine.	Approved, Withdrawn
Sulpiride	The risk or severity of adverse effects can be increased when Acepromazine is combined with Sulpiride.	Approved
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Acepromazine.	Approved, Investigational
Suvorexant	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
tafenoquine	The serum concentration of Acepromazine can be increased when it is combined with tafenoquine.	Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tasimelteon.	Approved
Tedizolid Phosphate	The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Acepromazine.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Acepromazine.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acepromazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrodotoxin.	Investigational
Thalidomide	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Acepromazine is combined with Thiopental.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Acepromazine.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Acepromazine is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiapride.	Approved, Investigational
Tiletamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiletamine.	Vet Approved
Timolol	Acepromazine may increase the hypotensive activities of Timolol.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tolcapone.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Acepromazine is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Acepromazine.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Acepromazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Acepromazine can be increased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Triprolidine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Acepromazine.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acepromazine.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Acepromazine is combined with Vigabatrin.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Acepromazine is combined with Vilazodone.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Vortioxetine.	Approved
Xylazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Acepromazine.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Acepromazine is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acepromazine.	Approved, Investigational
Zolpidem	Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Acepromazine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Acepromazine.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Acepromazine is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Avoid alcohol
Take with food to reduce irritation

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15552
KEGG Drug	D02604
PubChem Compound	6077
PubChem Substance	46508205
ChemSpider	5852
BindingDB	50131719
ChEBI	44932
ChEMBL	CHEMBL39560
PharmGKB	PA164783999
HET	PMZ
Drug Product Database	8035
Wikipedia	Acepromazine

ATC Codes

N05AA04 — Acepromazine

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Liquid

Experimental Properties

Property	Value	Source
melting point (°C)	< 25 °C	PhysProp
boiling point (°C)	230 °C at 5.00E-01 mm Hg	PhysProp

Predicted Properties

Property	Value	Source
Water Solubility	0.0098 mg/mL	ALOGPS
logP	4.32	ALOGPS
logP	3.49	ChemAxon
logS	-4.5	ALOGPS
pKa (Strongest Acidic)	16.06	ChemAxon
pKa (Strongest Basic)	8.5	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	23.55 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	99.35 m³·mol^-1	ChemAxon
Polarizability	37.17 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9852
Blood Brain Barrier	+	0.9844
Caco-2 permeable	+	0.8203
P-glycoprotein substrate	Substrate	0.8092
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Inhibitor	0.857
Renal organic cation transporter	Inhibitor	0.7087
CYP450 2C9 substrate	Non-substrate	0.7438
CYP450 2D6 substrate	Substrate	0.8618
CYP450 3A4 substrate	Substrate	0.6468
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Non-inhibitor	0.9319
CYP450 2D6 inhibitor	Inhibitor	0.9115
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.9105
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7333
Ames test	Non AMES toxic	0.849
Carcinogenicity	Non-carcinogens	0.9292
Biodegradation	Not ready biodegradable	0.9829
Rat acute toxicity	2.7963 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9537
hERG inhibition (predictor II)	Inhibitor	0.7813

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (7.84 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
GC-MS	GC-MS Spectrum - EI-B	splash10-0a4i-9110000000-bd29071c9502d119fa54	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0009000000-ba8f0be449800ec10cf1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-002r-9025000000-028fcf239ba77c5d26d0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-000i-9060000000-33b3210f75c9aa6899f3	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0abi-9180000000-9b10f7d22435e199c283	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-9670000000-0c65cbf1672ae4899236	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Benzothiazines

Direct Parent

Phenothiazines

Alternative Parents

Alkyldiarylamines / Diarylthioethers / Acetophenones / Aryl alkyl ketones / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives

Substituents

Phenothiazine / Alkyldiarylamine / Diarylthioether / Acetophenone / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

phenothiazines, tertiary amino compound, methyl ketone, aromatic ketone (CHEBI:44932 )

Targets

Details

1. D(2) dopamine receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Potassium channel regulator activity
Specific Function:: Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:: DRD2
Uniprot ID:: P14416
Uniprot Name:: D(2) dopamine receptor
Molecular Weight:: 50618.91 Da

References

Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]

Details

2. D(1A) dopamine receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: G-protein coupled amine receptor activity
Specific Function:: Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:: DRD1
Uniprot ID:: P21728
Uniprot Name:: D(1A) dopamine receptor
Molecular Weight:: 49292.765 Da

References

Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]

Details

3. 5-hydroxytryptamine receptor 2A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Virus receptor activity
Specific Function:: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:: HTR2A
Uniprot ID:: P28223
Uniprot Name:: 5-hydroxytryptamine receptor 2A
Molecular Weight:: 52602.58 Da

References

Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]

Details

4. 5-hydroxytryptamine receptor 1A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Serotonin receptor activity
Specific Function:: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:: HTR1A
Uniprot ID:: P08908
Uniprot Name:: 5-hydroxytryptamine receptor 1A
Molecular Weight:: 46106.335 Da

References

Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134 ]
Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039 ]

Details

5. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1A
Uniprot ID:: P35348
Uniprot Name:: Alpha-1A adrenergic receptor
Molecular Weight:: 51486.005 Da

References

Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]

Details

6. Alpha-1B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1B
Uniprot ID:: P35368
Uniprot Name:: Alpha-1B adrenergic receptor
Molecular Weight:: 56835.375 Da

References

Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]

Carriers

Details

1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Toxic substance binding
Specific Function:: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:: ALB
Uniprot ID:: P02768
Uniprot Name:: Serum albumin
Molecular Weight:: 69365.94 Da

References

Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Details

1. Solute carrier family 22 member 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Secondary active organic cation transmembrane transporter activity
Specific Function:: Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:: SLC22A1
Uniprot ID:: O15245
Uniprot Name:: Solute carrier family 22 member 1
Molecular Weight:: 61153.345 Da

References

Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]

Drug created on August 29, 2007 14:12 / Updated on September 01, 2017 10:41

Structure for DB01614 (Acepromazine)

Targets

References

References

References

References

References

References

Carriers

References

Transporters

References